Ionis to host 2025 virtual Annual Meeting of Stockholders
The agenda for the event is as follows:
-
5:00 p.m. –5:15 p.m. ET (2:00 p.m. –2:15 p.m. PT ) – Virtual Annual Meeting of Stockholders-
All stockholders of record at the close of business on
April 7, 2025 , are invited to participate in the virtual Annual Meeting webcast, which will be broadcast live at www.virtualshareholdermeeting.com/IONS2025. - Stockholders of record will receive an official proxy card from their brokerage firm. Each proxy card contains a 16-digit control number required to log-in, vote and submit questions during the webcast
-
Ionis does not provide proxy cards or have access to proxy card information, including 16-digit control numbers. For help obtaining a proxy card, locating your control number or for instructions to access the webcast, stockholders of record should contact their brokerage firm before
Thursday, May 22 . - A help line will be available on the registration page of the live webcast for participants requiring technical assistance in accessing or participating during the live event. There will not be a replay of this session.
-
All stockholders of record at the close of business on
-
5:30 p.m. ET (2:30 p.m. PT ) – Virtual corporate update-
Brett P. Monia , Ph.D., Ionis’ chief executive officer, will provide a general corporate update. - The presentation will be followed by a question-and-answer session. Instructions on how to submit the questions will be shared at the beginning of the session.
- All interested parties may access the webcast live at https://event.webcasts.com/starthere.jsp?ei=1712421&tp_key=7d89cf170d. An archived replay of the webcast will be posted for a limited time following the meeting at that same address.
-
About
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250506437079/en/
Ionis Pharmaceuticals Investor Contact:
Ionis Pharmaceuticals Media Contact:
Source:
